Types of bcr-abl and their correlations with the blood count in chronic myeloid leukemia (CML) in Togo

被引:3
作者
Padaro, Essohana [1 ]
Magnang, Flezouwe [2 ]
Layibo, Yao [1 ]
Mawussi, Koffi [3 ]
Kueviakoe, Irenee Messanh [2 ]
Agbetiafa, Kossi [2 ]
Vovor, Ahoefa [2 ]
机构
[1] Univ Lome, Serv Hematol, CHU Campus, Lome, Togo
[2] Univ Lome, Serv Hematol, CHU Tokoin, Lome, Togo
[3] Univ Kara, CHU Kara, Serv Hematol, Kara, Togo
关键词
Chronic myeloid leukemia; bcr-abl; Lome (Togo);
D O I
10.11604/pamj.2018.30.221.9821
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
This study aims to describe the different bcr-abl gene transcript variants in order to determine their frequency and to study their influence on CBC diagnostic test. We conducted a cross-sectional study of 34 patients with chronic myeloid leukemia in Togo. The search for fusion transcripts was performed in the laboratory of biological haematology at the Henri Mondor Hospital, Creteil (France). The average age of patients was 42,32 +/- 14,87 years ranging between 9 and 65 years. Most patients were male, with a sex- ratio of 1.61 (21 men and 13 women). Molecular examination showed b3-a2 transcript and b2-a2 transcript. Nineteen patients (55.88%) expressed b3-a2 transcript, 13 patients (38.24%) b2-a2 transcript (32.10%) and two patients expressed both b3-a2 and b2-a2 transcripts (5.88%). At diagnosis, mean hemoglobin level, the average number of white blood cells and the average number of platelets in patients expressing b3-a2 transcript were 99,2g/L; 207,63g/l and 451,28g/l respectively. In patients expressing b2-a2 transcript values were 104,6g/l, 114,32g/l and 486;11g/l. In patients with both transcripts, values were 67g/L, 867g/l and 780g/l respectively. CBC parameters are more significantly altered in patients with both transcripts b3-a2 and b2-a2.
引用
收藏
页数:5
相关论文
共 17 条
[1]  
Brousted A., 1994, PRECIS MALADIES SANG, VII, P24
[2]  
de Souza CA, 2005, HAEMATOLOGICA, V90, P232
[3]  
Diop S, 2004, Dakar Med, V49, P106
[4]  
Dokekias A Elira, 2003, Tunis Med, V81, P172
[5]   Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. [J].
Druker, BJ ;
Talpaz, M ;
Resta, DJ ;
Peng, B ;
Buchdunger, E ;
Ford, JM ;
Lydon, NB ;
Kantarjian, H ;
Capdeville, R ;
Ohno-Jones, S ;
Sawyers, CL .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1031-1037
[6]   POSSIBLE CORRELATION OF B3-A2-TYPE BCR-ABL MESSENGER-RNA DEFINED BY SEMIQUANTITATIVE RT-PCR TO PLATELET AND MEGAKARYOCYTE COUNTS IN PHILADELPHIA-POSITIVE CHRONIC MYELOGENOUS LEUKEMIA [J].
INOKUCHI, K ;
FUTAKI, M ;
DAN, K ;
NOMURA, T .
INTERNAL MEDICINE, 1994, 33 (04) :189-192
[7]  
INOKUCHI K, 1991, BLOOD, V78, P3125
[8]  
Martiat P, 1989, LEUKEMIA, V41, P363
[9]  
Messanh Kueviakoe I.`, 2015, CLIN MED RES, V4, P111, DOI [10.11648/j.cmr.20150404.14, DOI 10.11648/J.CMR.20150404.14]
[10]  
Mukiibi J M, 2003, East Afr Med J, V80, P470